HC Wainwright Forecasts XOMA’s FY2025 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – HC Wainwright increased their FY2025 earnings per share estimates for XOMA in a research report issued on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.17 for the year, up from their prior estimate of $0.15. HC Wainwright has a “Buy” rating and a $117.00 price objective on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for XOMA’s FY2026 earnings at $0.64 EPS.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.57%. The firm had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million.

Separately, StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $31.26 on Monday. The firm’s 50 day moving average is $28.57 and its two-hundred day moving average is $26.82. The firm has a market capitalization of $365.87 million, a P/E ratio of -8.98 and a beta of 0.90. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15. XOMA has a 52 week low of $14.33 and a 52 week high of $33.78.

Hedge Funds Weigh In On XOMA

Several large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in shares of XOMA by 55.6% during the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,266 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in shares of XOMA in the 1st quarter worth $212,000. Rhumbline Advisers lifted its holdings in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the period. Ellsworth Advisors LLC bought a new position in XOMA during the third quarter valued at about $516,000. Finally, Bank of New York Mellon Corp grew its holdings in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 1,968 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.